ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

BetterWay Blood Testing by Babson Diagnostics Achieves SOC 2 Compliance

AUSTIN, TX / ACCESS Newswire / December 16, 2025 / BetterWay blood testing by Babson Diagnostics, a science-first healthcare technology company transforming diagnostic blood testing, announced today that it has achieved SOC 2 type I compliance through a third-party audit of its information security and privacy controls. Compliance with SOC 2's high standards reflects Babson Diagnostics' commitment to secure and patient-centered healthcare.

The SOC 2 attestation report affirms that Babson's information systems are properly designed to meet the security, availability, processing integrity, confidentiality, and privacy criteria established by the American Institute of Certified Public Accountants (AICPA). The voluntary audit was completed by independent third-party assessor A-Lign. Babson is committed to providing a patient-preferred blood testing experience, and ensuring the security and privacy of patients' data has always been a cornerstone of that effort.

"Our partners expect their customers' information to be handled with the utmost diligence and care," said C.J. Singh, Vice President of Information Operations at Babson Diagnostics. "SOC 2 compliance validates both our ability to meet their high standards and, more importantly still, our commitment to providing a blood-testing journey that patients can trust."

Babson Diagnostics continues to grow its network of partners that provide access to BetterWay's patient-friendly fingertip testing, including select Sam's Club, H-E-B, and Peoples Rx locations. SOC 2 compliance attests its capacity to meet the uncompromising security standards that large and responsible enterprises are expected to uphold.

About BetterWay Blood Testing by Babson Diagnostics

BetterWay is blood testing reimagined-patient-friendly fingertip collection with automated sample preparation and accurate lab results. One in three people skip blood testing due to anxiety, fear of needles, difficult venous access, or inconvenience. BetterWay enables blood testing without phlebotomy. This improves patient experience, increases adherence to testing, optimizes staffing efficiency, and advances health equity. BetterWay was developed by Babson Diagnostics, a science-first healthcare technology company that has become the global leader in the use of capillary blood for routine testing. Babson was named 2024 Medtech Company of the Year by MD + DI, 2025 SXSW Innovation Award winner for Health & Biotech, and one of Fast Company's 2025 Most Innovative Companies in Healthcare. For more information, please visit BetterWay.com or connect with us on Instagram or LinkedIn.

Media Contact:

Ray Young
512.694.6097
ray@razorsharppr.com

# # #

SOURCE: BetterWay Blood Testing



View the original press release on ACCESS Newswire

Recent Quotes

View More
Symbol Price Change (%)
AMZN  226.50
-4.32 (-1.87%)
AAPL  271.01
-0.85 (-0.31%)
AMD  223.47
+9.31 (4.35%)
BAC  55.95
+0.95 (1.73%)
GOOG  315.32
+1.52 (0.48%)
META  650.41
-9.68 (-1.47%)
MSFT  472.94
-10.68 (-2.21%)
NVDA  188.85
+2.35 (1.26%)
ORCL  195.71
+0.80 (0.41%)
TSLA  438.07
-11.65 (-2.59%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.